{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:32:49Z","timestamp":1784759569399,"version":"3.55.0"},"reference-count":68,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2023,8,4]]},"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Acute respiratory distress syndrome (ARDS) is the most severe form of lung injury, rendering gaseous exchange insufficient, leading to respiratory failure. Despite over 50 years of research on the treatment of ARDS when developed from illnesses such as sepsis and pneumonia, mortality remains high, and no robust pharmacological treatments exist. The progression of SARS-CoV-2 infections to ARDS during the recent global pandemic led to a surge in the number of clinical trials on the condition. Understandably, this explosion in new research focused on COVID-19 ARDS (CARDS) rather than ARDS when developed from other illnesses, yet differences in pathology between the two conditions mean that optimal treatment for them may be distinct.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>The aim of the present work is to assess whether new therapeutic interventions that have been developed for the treatment of CARDS may also hold strong potential in the treatment of ARDS when developed from other illnesses. The study objectives are achieved through a systematic review of clinical trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The COVID-19 pandemic led to the identification of various therapeutic interventions for CARDS, some but not all of which are optimal for the management of ARDS. Interventions more suited to CARDS pathology include antithrombotics and biologic agents, such as cytokine inhibitors. Cell-based therapies, on the other hand, show promise in the treatment of both conditions, attributed to their broad mechanisms of action and the overlap in the clinical manifestations of the conditions. A shift towards personalised treatments for both CARDS and ARDS, as reflected through the increasing use of biologics, is also evident.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>As ongoing CARDS clinical trials progress, their findings are likely to have important implications that alter the management of ARDS in patients that develop the condition from illnesses other than COVID-19 in the future.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjresp-2022-001525","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T11:23:39Z","timestamp":1693567419000},"page":"e001525","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Acute respiratory distress syndrome: potential of therapeutic interventions effective in treating progression from COVID-19 to treat progression from other illnesses\u2014a systematic review"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct03376854","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04384445","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04629105","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04798716","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04905836","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03799874","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04412057","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04355728","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04357730","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04412057","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04369469","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04357730","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00431379","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04357730","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02804945","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02097641","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04345601","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04629105","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04490486","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04384445","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04355728","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04371393","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04798716","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04399889","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04905836","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03042143","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02097641","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04355728","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00112164","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04397510","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04870125","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02425579","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03799874","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00434993","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01274481","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04417036","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00004494","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04360096","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01597635","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04778059","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00112164","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04397510","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04870125","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03799874","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02425579","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01274481","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00004494","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04360096","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01597635","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01597635","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01597635","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04778059","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04778059","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02622724","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00201409","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04616586","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04402060","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04351243","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Emma J","family":"Ragel","sequence":"first","affiliation":[{"name":"Division of Pharmacy and Optometry, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7709-5202","authenticated-orcid":false,"given":"Lynda K","family":"Harris","sequence":"additional","affiliation":[{"name":"Division of Pharmacy and Optometry, University of Manchester, Manchester, UK"},{"name":"Maternal and Fetal Health Research Centre, University of Manchester, Manchester, UK"},{"name":"3St Mary\u2019s Hospital, Manchester University NHS Foundation Trust, Manchester, UK"},{"name":"Olson Center for Women's Health, University of Nebraska Medical Center, Omaha, Nebraska, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6296-314X","authenticated-orcid":false,"given":"Richard A","family":"Campbell","sequence":"additional","affiliation":[{"name":"Division of Pharmacy and Optometry, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"key":"2025083112382337000_10.1.e001525.1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-208402"},{"key":"2025083112382337000_10.1.e001525.2","doi-asserted-by":"publisher","DOI":"10.1097\/PSY.0b013e31816aa0dd"},{"key":"2025083112382337000_10.1.e001525.3","doi-asserted-by":"publisher","DOI":"10.1186\/cc121"},{"key":"2025083112382337000_10.1.e001525.4","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1016\/j.chest.2020.06.080","article-title":"Evidence-based practices for acute respiratory failure and acute respiratory distress syndrome: a systematic review of reviews","volume":"158","author":"Ervin","year":"2020","journal-title":"Chest"},{"key":"2025083112382337000_10.1.e001525.5","first-page":"S435","article-title":"Acute respiratory distress syndrome and pneumothorax","volume":"6","author":"Terzi","year":"2014","journal-title":"J Thorac Dis"},{"key":"2025083112382337000_10.1.e001525.6","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00311.2013"},{"key":"2025083112382337000_10.1.e001525.7","doi-asserted-by":"crossref","unstructured":"Cardinal-Fernandez P , Ballen Barragan A , Lorente J . ARDS: A Clinical Syndrome or A Pathological Entity? Annual Update in Intensive Care and Emergency Medicine 2014, 1st ed. Cham: Springer, 2014: 219\u201327.","DOI":"10.1007\/978-3-319-03746-2_17"},{"key":"2025083112382337000_10.1.e001525.8","doi-asserted-by":"crossref","unstructured":"Coudroy R , Boissier F , Thille A . Acute Respiratory Distress Syndrome (ARDS): Definition, Incidence and Outcome. Acute Respiratory Distress Syndrome, 1st ed. Cham: Springer, 2017: 1\u201314.","DOI":"10.1007\/978-3-319-41852-0_1"},{"key":"2025083112382337000_10.1.e001525.9","doi-asserted-by":"crossref","unstructured":"Silva P , Rocco P . Pathophysiology of Acute Respiratory Distress Syndrome. Acute Respiratory Distress Syndrome, 1st ed. Cham: Springer, 2017: 15\u201323.","DOI":"10.1007\/978-3-319-41852-0_2"},{"key":"2025083112382337000_10.1.e001525.10","first-page":"7","article-title":"Acute respiratory distress syndrome: pathophysiology and therapeutic options","volume":"4","author":"Pierrakos","year":"2012","journal-title":"J Clin Med Res"},{"key":"2025083112382337000_10.1.e001525.11","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.F305"},{"key":"2025083112382337000_10.1.e001525.12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-019-0069-0","article-title":"Acute respiratory distress syndrome","volume":"5","author":"Matthay","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2025083112382337000_10.1.e001525.13","unstructured":"Davies A , Moore C . The respiratory system: basic science and clinical conditions, 2nd ed. Edinburgh: Churchill Livingstone, 2014: 11\u201369."},{"key":"2025083112382337000_10.1.e001525.14","unstructured":"Lawrence H , Moore T . Crash course respiratory medicine, 5th ed. London: Elsevier Limited, 2019: 3\u201370."},{"key":"2025083112382337000_10.1.e001525.15","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201411-507FR"},{"key":"2025083112382337000_10.1.e001525.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1608077"},{"key":"2025083112382337000_10.1.e001525.17","doi-asserted-by":"publisher","DOI":"10.1136\/thx.53.10.815"},{"key":"2025083112382337000_10.1.e001525.18","doi-asserted-by":"crossref","unstructured":"Lewis SR , Pritchard MW , Thomas CM , et al . Pharmacological agents for adults with acute respiratory distress syndrome. Cochrane Database Syst Rev 2019. doi:10.1002\/14651858.CD004477.pub3","DOI":"10.1002\/14651858.CD004477.pub3"},{"key":"2025083112382337000_10.1.e001525.19","doi-asserted-by":"publisher","DOI":"10.4187\/respcare.01366"},{"key":"2025083112382337000_10.1.e001525.20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/CNQ.0000000000000275","article-title":"Complications and outcomes of acute respiratory distress syndrome","volume":"42","author":"DiSilvio","year":"2019","journal-title":"Crit Care Nurs Q"},{"key":"2025083112382337000_10.1.e001525.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1208707"},{"key":"2025083112382337000_10.1.e001525.22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.3.374"},{"key":"2025083112382337000_10.1.e001525.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1005372"},{"key":"2025083112382337000_10.1.e001525.24","article-title":"Acute respiratory distress syndrome and the use of inhaled pulmonary vasodilators in the COVID-19 era: a narrative review","volume":"12","author":"Nasrullah","year":"2022","journal-title":"Life (Basel)"},{"key":"2025083112382337000_10.1.e001525.25","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201012-2090OC"},{"key":"2025083112382337000_10.1.e001525.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61623-1"},{"key":"2025083112382337000_10.1.e001525.27","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201308-1549OC"},{"key":"2025083112382337000_10.1.e001525.28","doi-asserted-by":"crossref","unstructured":"Hyzy RC , McSparron J . Evidence-based critical care. In: Hyzy R , McSparron J , eds. Management of Acute Respiratory Distress Syndrome, 2nd ed. Cham: Springer, 2020: 162\u20137. doi:10.1007\/978-3-030-26710-0","DOI":"10.1007\/978-3-030-26710-0"},{"key":"2025083112382337000_10.1.e001525.29","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s00134-014-3578-z","article-title":"Future therapies for ARDS","volume":"41","author":"Curley","year":"2015","journal-title":"Intensive Care Med"},{"key":"2025083112382337000_10.1.e001525.30","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmni.2021.100944","article-title":"Neutrophils and secondary infections in COVID-19 induced acute respiratory distress syndrome","volume":"44","author":"Holliday","year":"2021","journal-title":"New Microbes New Infect"},{"key":"2025083112382337000_10.1.e001525.31","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2021-216904"},{"key":"2025083112382337000_10.1.e001525.32","doi-asserted-by":"crossref","DOI":"10.1186\/s41479-021-00092-9","article-title":"Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management","volume":"13","author":"Aslan","year":"2021","journal-title":"Pneumonia (Nathan)"},{"key":"2025083112382337000_10.1.e001525.33","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00134-020-06251-8","article-title":"Correction to: clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS","volume":"47","author":"Ferrando","year":"2021","journal-title":"Intensive Care Med"},{"key":"2025083112382337000_10.1.e001525.34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n436"},{"key":"2025083112382337000_10.1.e001525.35","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-021-03748-6","article-title":"Isn\u2019t it time to abandon ARDS? The COVID-19 lesson","volume":"25","author":"Gattinoni","year":"2021","journal-title":"Crit Care"},{"key":"2025083112382337000_10.1.e001525.36","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202004-1226LE"},{"key":"2025083112382337000_10.1.e001525.37","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1513\/AnnalsATS.202008-1026OC","article-title":"COVID-19 versus non\u2013COVID-19 acute respiratory distress syndrome: comparison of demographics, physiologic parameters, inflammatory biomarkers, and clinical outcomes","volume":"18","author":"Bain","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"2025083112382337000_10.1.e001525.38","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153173","article-title":"Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome","volume":"132","author":"Perlin","year":"2022","journal-title":"J Clin Invest"},{"key":"2025083112382337000_10.1.e001525.39","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50674"},{"key":"2025083112382337000_10.1.e001525.40","doi-asserted-by":"crossref","unstructured":"Perlin DS , Neil GA , Anderson C , et al . CERC-002, a human anti-LIGHT MAB reduces respiratory failure and death in hospitalized COVID-19 ARDS patients. Pharmacol Ther [Preprint] 2021. doi:10.1101\/2021.04.03.21254748","DOI":"10.1101\/2021.04.03.21254748"},{"key":"2025083112382337000_10.1.e001525.41","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-021-00519-4"},{"key":"2025083112382337000_10.1.e001525.42","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2147\/ITT.S262566","article-title":"GM-CSF: a promising target in inflammation and autoimmunity","volume":"9","author":"Lee","year":"2020","journal-title":"Immunotargets Ther"},{"key":"2025083112382337000_10.1.e001525.43","doi-asserted-by":"crossref","unstructured":"Javitt JC . Perspective: the potential role of vasoactive intestinal peptide in treating COVID-19. Preprints [Preprint] 2020. doi:10.22541\/au.158940764.42332418","DOI":"10.22541\/au.158940764.42332418"},{"key":"2025083112382337000_10.1.e001525.44","doi-asserted-by":"crossref","unstructured":"Zanirati G , Provenzi L , Libermann LL , et al . Stem cell-based therapy for COVID-19 and ARDS: a systematic review. Npj Regen Med 2021;6. doi:10.1038\/s41536-021-00181-9","DOI":"10.1038\/s41536-021-00181-9"},{"key":"2025083112382337000_10.1.e001525.45","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2023.156287","article-title":"Emerging aspects of cytokine storm in COVID-19: the role of proinflammatory cytokines and therapeutic prospects","volume":"169","author":"Dharra","year":"2023","journal-title":"Cytokine"},{"key":"2025083112382337000_10.1.e001525.46","doi-asserted-by":"crossref","unstructured":"Youssef JG , Said S , Youssef G , et al . Treatment of acute respiratory distress syndrome with vasoactive intestinal peptide. Medicine & Pharmacology [Preprint] 2020. doi:10.20944\/preprints202007.0453.v1","DOI":"10.20944\/preprints202007.0453.v1"},{"key":"2025083112382337000_10.1.e001525.47","doi-asserted-by":"crossref","first-page":"666629","DOI":"10.3389\/fmed.2021.666629","article-title":"Comparative study of acute lung injury in COVID-19 and non-COVID-19 patients","volume":"8","author":"Zhang","year":"2021","journal-title":"Front Med"},{"key":"2025083112382337000_10.1.e001525.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccc.2021.05.001"},{"key":"2025083112382337000_10.1.e001525.49","doi-asserted-by":"crossref","first-page":"908","DOI":"10.21037\/atm-22-3717","article-title":"A narrative review of COVID-19-related acute respiratory distress syndrome (CARDS): 'typical' or 'atypical' ARDS","volume":"10","author":"Pu","year":"2022","journal-title":"Ann Transl Med"},{"key":"2025083112382337000_10.1.e001525.50","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1109\/JSYST.2013.2260091","article-title":"Systems-of-systems perspective on healthcare: insights from two multi-method exploratory cases of leading U.S. and U.K. hospitals","volume":"8","author":"Fradinho","year":"2014","journal-title":"IEEE Systems Journal"},{"key":"2025083112382337000_10.1.e001525.51","doi-asserted-by":"publisher","DOI":"10.1007\/BF01704707"},{"key":"2025083112382337000_10.1.e001525.52","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S2213-2600(18)30418-1","article-title":"Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2A safety trial","volume":"7","author":"Matthay","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2025083112382337000_10.1.e001525.53","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-017-1823-x","article-title":"A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome","volume":"21","author":"Khan","year":"2017","journal-title":"Crit Care"},{"key":"2025083112382337000_10.1.e001525.54","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.chest.2021.09.024","article-title":"Study of Alteplase for respiratory failure in SARS-CoV-2 COVID-19","volume":"161","author":"Barrett","year":"2022","journal-title":"Chest"},{"key":"2025083112382337000_10.1.e001525.55","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020264","article-title":"Circulating LIGHT (TNFSF14) and Interleukin-18 levels in sepsis-induced multi-organ injuries","volume":"10","author":"Qu","year":"2022","journal-title":"Biomedicines"},{"key":"2025083112382337000_10.1.e001525.56","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s40121-021-00425-7","article-title":"Pharmacokinetic and pharmacodynamic evaluation of ravulizumab in adults with severe coronavirus disease 2019","volume":"10","author":"McEneny-King","year":"2021","journal-title":"Infect Dis Ther"},{"key":"2025083112382337000_10.1.e001525.57","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.808797","article-title":"The role of Interleukin-8 in lung inflammation and injury: implications for the management of COVID-19 and hyperinflammatory acute respiratory distress syndrome","volume":"12","author":"Cesta","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025083112382337000_10.1.e001525.58","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140711","article-title":"The complement system in COVID-19: friend and foe?","volume":"5","author":"Java","year":"2020","journal-title":"JCI Insight"},{"key":"2025083112382337000_10.1.e001525.59","doi-asserted-by":"publisher","DOI":"10.2174\/138920111798281171"},{"key":"2025083112382337000_10.1.e001525.60","doi-asserted-by":"crossref","DOI":"10.1186\/s40635-020-0292-8","article-title":"Carbon Monoxide in intensive care medicine\u2014time to start the therapeutic application","volume":"8","author":"Goebel","year":"2020","journal-title":"Intensive Care Med Exp"},{"key":"2025083112382337000_10.1.e001525.61","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2014.05.005"},{"key":"2025083112382337000_10.1.e001525.62","doi-asserted-by":"crossref","first-page":"165","DOI":"10.5847\/wjem.j.1920-8642.2015.03.001","article-title":"Albuterol in the treatment of acute respiratory distress syndrome: a meta-analysis of randomized controlled trials","volume":"6","author":"Wu","year":"2015","journal-title":"World J Emerg Med"},{"key":"2025083112382337000_10.1.e001525.63","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.572009","article-title":"Targeting neutrophils to treat acute respiratory distress syndrome in Coronavirus disease","volume":"11","author":"Chiang","year":"2020","journal-title":"Front Pharmacol"},{"key":"2025083112382337000_10.1.e001525.64","doi-asserted-by":"crossref","first-page":"1470320320972015","DOI":"10.1177\/1470320320972015","article-title":"Central involvement of SARS-CoV-2 may aggravate ARDS and hypertension","volume":"21","author":"Cure","year":"2020","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"2025083112382337000_10.1.e001525.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.wem.2011.09.002"},{"key":"2025083112382337000_10.1.e001525.66","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.cmi.2022.04.018","article-title":"Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2025083112382337000_10.1.e001525.67","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1093\/cid\/ciac443","article-title":"Effectiveness of Paxlovid in reducing severe Coronavirus disease 2019 and mortality in high-risk patients","volume":"76","author":"Najjar-Debbiny","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025083112382337000_10.1.e001525.68","article-title":"Efficacy of Molnupiravir for the treatment of mild or moderate COVID-19 in adults: a meta-analysis","volume":"15","author":"Benaicha","year":"2023","journal-title":"Cureus"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2022-001525","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T19:38:42Z","timestamp":1756669122000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2022-001525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,9,1]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1136\/bmjresp-2022-001525"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2022-001525","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}